Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023 ...Middle East

Late Breaking Poster Presentation Reports New Results Demonstrating Robust Liver Fat Reductions Across Key Subgroups, Including Patients with Type 2 Diabetes and Among Those with F2 or F3 Fibrosis Presentation also Highlights Previously Reported Results Showing Successful Achievement of...

Hence then, the article about viking therapeutics presents new data from phase 2b voyage study of vk2809 in patients with biopsy confirmed non alcoholic steatohepatitis nash at the liver meeting 2023 was published today ( Tuesday 14/11/2023 - 12:05 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Viking Therapeutics Presents New Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) at The Liver Meeting® 2023 )

Also on site :

• The Middle East war is testing the Gulf’s ambitions to become an AI hub
• Move over, seltzer. Non-carbonated drinks are taking the spotlight
• Man dies in northeast Australia after shark attack